Meeting
2022 ASCO Annual Meeting
Rationale and design of phase 1 FTIH study of FOXP3 antisense oligonucleotide AZD8701 in patients with selected advanced solid tumors.
Authors
Michele Petruzzelli
AstraZeneca, Cambridge, MD, United Kingdom
Michele Petruzzelli , Sophie Postel-Vinay , Elena Garralda , John D. Powderly , Melissa Lynne Johnson , Eduardo Castanon Alvarez , Christos Kyriakopoulos , Rafael Villanueva , Funda Meric-Bernstam , Cesar Augusto Santa-Maria , Mateusz Opyrchal , John Stone , Frederick Goldberg , Stephen McMorn , Tinnu Sarvotham , Alvin Milner , Helen Angell , Teresa Collins , Christophe Massard , Lillian L. Siu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT04504669
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3166)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3166
Abstract #
TPS3166
Poster Bd #
150a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.
First Author: Jordi Rodon Ahnert
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
First Author: Iwona A. Lugowska
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal
Poster
2023 ASCO Annual Meeting
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).
First Author: Nicholas Coupe